Management of Antithrombotic Therapy in Patients with Cardiovascular Disease

Introduction to Antithrombotic Therapy Management

The American College of Chest Physicians recommends discontinuing Lovenox when starting dual antiplatelet therapy with Plavix and aspirin in patients with cardiovascular disease, as the combination of therapeutic anticoagulation with dual antiplatelet therapy creates excessive bleeding risk without additional benefit for most cardiovascular conditions 1, 2

The European Society of Cardiology suggests that prophylactic-dose LMWH is only indicated for immobilized patients with acute stroke or those with specific VTE risk factors, not for routine cardiovascular disease management 1
The European Heart Association recommends not using triple therapy (therapeutic anticoagulation + Plavix + aspirin) beyond 1 month maximum, as this substantially increases major bleeding risk by 40-50% 2, 3

The European Society of Cardiology recommends transitioning to dual therapy (anticoagulation + single antiplatelet agent) after the acute period, using clopidogrel as the preferred antiplatelet agent over aspirin when combined with anticoagulation 2, 4
The American Heart Association suggests considering switching from Lovenox to a DOAC (such as apixaban or rivaroxaban) for long-term management, as DOACs have lower bleeding risk than LMWH when combined with antiplatelet therapy 2, 4

The European Heart Association recommends determining if therapeutic anticoagulation is absolutely required (atrial fibrillation, mechanical valve, acute VTE), and if not, discontinuing Lovenox and using dual antiplatelet therapy only for acute coronary syndrome or aspirin/clopidogrel monotherapy for stable disease 1, 5
The American College of Cardiology suggests assessing timing from acute coronary event and using anticoagulation + clopidogrel only (stop aspirin and Lovenox) for 1-12 months post-PCI/ACS 2, 4

The European Society of Cardiology recommends avoiding NSAIDs and optimizing blood pressure control to minimize bleeding risk when any antithrombotic combination is necessary 6, 3
The American Heart Association suggests not continuing triple therapy beyond the acute period, as this is the most common error leading to preventable major bleeding 3